NeuroAiD Safe Treatment Registry
Launched by CHIMES SOCIETY · Aug 26, 2015
Trial Information
Current as of August 27, 2025
Recruiting
Keywords
ClinConnect Summary
The NeuroAiD Safe Treatment Registry is a study that looks at how safe and effective NeuroAiD is for people who have suffered brain injuries. This registry is a partnership between industry experts and researchers, and it aims to collect real-world information about patients using NeuroAiD. If you or someone you know has been prescribed NeuroAiD, you could be part of this study, regardless of age or gender, as long as you are willing to share your treatment experience.
As a participant, you would provide some basic information about your health and treatment, which will be stored in a secure online system. This study is currently recruiting participants, and it’s important to note that you should not join if you have any reasons that might prevent you from safely using NeuroAiD or if you’re not comfortable participating. Your involvement could help improve our understanding of this treatment for brain injuries and contribute to better care for others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female
- • Any age
- • Taking, or has been prescribed NeuroAiD for any duration as judged by the physician and/or the participant
- • Agrees to be included in the registry and allows retrieval and analysis of data in accordance with local requirements
- Exclusion Criteria:
- • Unwillingness to participate
- • Contraindication to NeuroAiD
About Chimes Society
Chimes Society is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative study designs and rigorous scientific methodologies. Committed to transparency and ethical practices, Chimes Society collaborates with healthcare professionals, research institutions, and regulatory bodies to facilitate the development of new therapies and interventions. By prioritizing patient safety and engagement, Chimes Society aims to contribute valuable insights to the medical community and enhance the overall effectiveness of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jakarta, , Indonesia
Kuala Lumpur, , Malaysia
Patients applied
Trial Officials
Narayanaswamy Venketasubramanian, FRCP
Study Chair
Raffles Neuroscience Centre, Raffles Hospital, Singapore
Ramesh Kumar, FRCS
Principal Investigator
Department of Neurosurgery, Faculty of Medicine, University Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
Lyna Soertidewi, MD
Principal Investigator
Department of Neurology, National Brain Center Hospital, Jakarta, Indonesia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials